Seattle Genetics Highlights Novel Antibody-Drug Conjugate Technologies & Immuno-Oncology Program Advances at the American Ass...
April 12 2018 - 8:00AM
Business Wire
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced data
highlights from nine presentations showcasing the company’s
innovative, proprietary antibody-drug conjugate (ADC) platform
technologies as well as its emerging immuno-oncology pipeline. Data
include preclinical and clinical advances with ADCETRIS®
(brentuximab vedotin), ladiratuzumab vedotin, SGN-CD48A and
SGN-2FF. Additionally, Seattle Genetics will present the first
preclinical data describing the novel empowered antibody SEA-BCMA.
These data will be presented at the American Association for Cancer
Research (AACR) Annual Meeting 2018 being held April 14-18, 2018 in
Chicago.
“We are an emerging multi-product company, advancing a
substantial pipeline of targeted therapies for patients with solid
tumors and blood cancers,” said Dennis Benjamin, Ph.D., Senior Vice
President of Research at Seattle Genetics. “New data featured in
nine presentations underscore our commitment to scientific
innovation and the needs of patients. These data presentations
highlight the potential combination of ADCs with checkpoint
inhibitors, novel ADC payloads, antibody masking technologies and
progress with our immuno-oncology program, SGN-2FF. We are also
presenting preclinical data for our new multiple myeloma program,
SEA-BCMA, which has a phase 1 study scheduled to start this
year.”
Abstracts can be found at www.aacr.org and include the
following:
- An oral presentation and poster
presentation on Sunday and Monday, April 15 and 16, 2018,
respectively (Abstracts #930, 2803), will showcase preclinical data
evaluating proprietary NAMPT inhibitors and auristatins as ADC
payloads. The data show NAMPT inhibitors have a unique mechanism of
action and encouraging therapeutic window. Preclinical data also
describe the development of novel auristatin payloads with
potential application across multiple tumor types.
- An innovative approach to masking
antibodies for tumor specific activation will be featured in a
poster presentation on Sunday, April 15, 2018 (Abstract #250).
Preclinical data demonstrate that coiled-coil masked antibodies and
ADCs show improved tolerability and equivalent antitumor activity
compared to unmasked counterparts. The data suggest this technology
may be applied to a range of antibodies or ADCs and could enable
their development against previously inaccessible cancer
targets.
- The novel preclinical program SEA-BCMA
will be highlighted in a poster presentation on Tuesday, April 17,
2018 (Abstract #3833). The cell surface protein BCMA is expressed
on cells of several cancer types, including multiple myeloma and
other B cell malignancies. SEA-BCMA is an antibody empowered using
Seattle Genetics’ proprietary Sugar Engineered Antibody (SEA)
technology designed to enhance antibody effector functions. The
preclinical data support initiation of a phase 1 trial for multiple
myeloma, which is planned for 2018.
- Clinical biomarker data from a phase 1
trial evaluating the novel immuno-oncology agent SGN-2FF in
patients with advanced solid tumors will be shown in a poster
presentation on Wednesday, April 18, 2018 (Abstract #5551). The
preliminary data demonstrate the biological effects of SGN-2FF and
support further development of this novel immuno-oncology
agent.
- Three poster presentations on Monday
and Wednesday, April 16 and 18, 2018 (Abstracts #1789, 2742, and
5619) will highlight preclinical data evaluating the ability of
ADCETRIS, ladiratuzumab vedotin and SGN-CD48A, each of which are
auristatin-based ADCs, to elicit additional mechanisms of action,
including immunogenic cell death. These data support clinical
evaluation in combination with checkpoint inhibitors. ADCETRIS and
ladiratuzumab vedotin are being evaluated in combination with
checkpoint inhibitors in multiple ongoing clinical trials.
About Seattle Genetics
Seattle Genetics is an innovative biotechnology company
dedicated to improving the lives of people with cancer through
targeted therapies. The company’s industry-leading antibody-drug
conjugate (ADC) technology harnesses the targeting ability of
antibodies to deliver cell-killing agents directly to cancer cells.
Seattle Genetics commercializes ADCETRIS® (brentuximab vedotin) for
the treatment of several types of CD30-expressing lymphomas. The
company is also advancing a robust pipeline of novel therapies for
solid tumors and blood-related cancers designed to address
significant unmet medical needs and improve treatment outcomes for
patients. More information can be found at www.seattlegenetics.com
and follow @SeattleGenetics on Twitter.
Forward-Looking Statements
Certain of the statements made in this press release are
forward-looking, such as those, among others, relating to the
possible utility or application of the Company’s technologies to
develop therapeutic agents, therapeutic potential of
investigational agents, and future development activities including
clinical trials. Actual results or developments may differ
materially from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include the
difficulty and uncertainty of pharmaceutical product development,
including the risks that Seattle Genetics may experience delays in
its planned clinical trial initiations or otherwise experience
failures or setbacks in its preclinical and clinical development
programs due to the potential lack of efficacy or risk of adverse
events as Seattle Genetics’ product candidates advance in
development or other factors. More information about the risks and
uncertainties faced by Seattle Genetics is contained under the
caption “Risk Factors” included in the company’s Annual Report on
Form 10-K for the year ended December 31, 2017 filed with the
Securities and Exchange Commission. Seattle Genetics disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180412005347/en/
Seattle Genetics, Inc.Investors:Peggy Pinkston,
425-527-4160ppinkston@seagen.comorMedia:Monique Greer,
425-527-4641mgreer@seagen.com
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From May 2023 to May 2024